Brief: Biogen Says Co Received European Commission Approval For High Dose Regimen Of SPINRAZA
12/01/2026 16:13
Jan 12 (Reuters) - Biogen Inc BIIB.O: BIOGEN RECEIVES EUROPEAN COMMISSION APPROVAL FOR HIGH DOSE REGIMEN OF SPINRAZA® (NUSINERSEN) FOR SPINAL MUSCULAR ATROPHY BIOGEN - HIGH DOSE SPINRAZA APPROVED IN JAPAN, DECISION EXPECTED BY APRIL 3, 2026 Source text: ID:nGNX2Kn9Sk Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors